Another example, aprotinin, is a naturally-occurring broad-spectrum protease inhibitor; some countries refuse to approve this medication because it supposedly has a greater mortality rate than its alternatives (tranexamic acid and aminocaproic acid) and causes damage to the kidneys and heart.
Aprotinin, a natural broad-spectrum protease inhibitor, is being rejected by certain nations because it's believed to have a higher fatality rate than tranexamic acid and aminocaproic acid, and may cause harm to the kidneys and heart.